nach oben

Current Diabetes Reports

Erschienen in:

01.12.2015 | Diabetes Epidemiology (NM Maruthur, Section Editor)

Betatrophin in Diabetes Mellitus: the Epidemiological Evidence in Humans

verfasst von: Daniel Espes, Mats Martinell, Hanna Liljebäck, Per-Ola Carlsson

Erschienen in: Current Diabetes Reports | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

The prevalence of type 2 diabetes is increasing worldwide, and while numerous treatments exist, none of the current pharmacologic therapies is curative. Pharmacologic approaches that increase beta cell mass may present an avenue for actual cure. There have been numerous reports on factors that can induce beta cell proliferation in rodents, whereas there are still very limited data on the occurrence of beta cell proliferation in humans. The recent discovery of the hormone betatrophin, which in mice counteracted glucose intolerance induced by insulin resistance by potently stimulating beta cell proliferation, has boosted the hope for a new target for drug development for the treatment of diabetes mellitus in humans. With the encouraging preclinical findings as a background, this review presents the available clinical data on betatrophin and discusses its possible role in humans.

Lam DW, LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes. 2012;19(2):93–6.CrossRefPubMed

Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC. Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care. 2006;29(3):717–8.CrossRefPubMed

Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–10.CrossRefPubMed

Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10 Suppl 4:32–42.CrossRefPubMed

Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia. 1983;24(5):366–71.CrossRefPubMed

Clark A, Jones LC, de Koning E, Hansen BC, Matthews DR. Decreased insulin secretion in type 2 diabetes: a problem of cellular mass or function? Diabetes. 2001;50 Suppl 1:S169–71.CrossRefPubMed

Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965;14(10):619–33.CrossRefPubMed

Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59(11):2846–53.PubMedCentralCrossRefPubMed

Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care. 2012;35(3):465–70.PubMedCentralCrossRefPubMed

10.

Oram RA, Jones AG, Besser RE, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia. 2014;57(1):187–91.PubMedCentralCrossRefPubMed

11.

Kulkarni RN, Mizrachi EB, Ocana AG, Stewart AF. Human beta-cell proliferation and intracellular signaling: driving in the dark without a road map. Diabetes. 2012;61(9):2205–13.PubMedCentralCrossRefPubMed

12.

Bernal-Mizrachi E, Kulkarni RN, Scott DK, Mauvais-Jarvis F, Stewart AF, Garcia-Ocana A. Human beta-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map. Diabetes. 2014;63(3):819–31.PubMedCentralCrossRefPubMed

13.

Stewart AF, Hussain MA, Garcia-Ocana A, et al. Human beta-cell proliferation and intracellular signaling: part 3. Diabetes. 2015;64(6):1872–85.CrossRefPubMed

14.

Wang P, Fiaschi-Taesch NM, Vasavada RC, Scott DK, Garcia-Ocana A, Stewart AF. Diabetes mellitus—advances and challenges in human beta-cell proliferation. Nat Rev Endocrinol. 2015;11(4):201–12.PubMed

15.

Gregg BE, Moore PC, Demozay D, et al. Formation of a human beta-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab. 2012;97(9):3197–206.PubMedCentralCrossRefPubMed

16.

Meier JJ, Butler AE, Saisho Y, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes. 2008;57(6):1584–94.PubMedCentralCrossRefPubMed

17.

Perl S, Kushner JA, Buchholz BA, et al. Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab. 2010;95(10):E234–9.PubMedCentralCrossRefPubMed

18.

Menge BA, Tannapfel A, Belyaev O, et al. Partial pancreatectomy in adult humans does not provoke beta-cell regeneration. Diabetes. 2008;57(1):142–9.CrossRefPubMed

19.

Butler AE, Cao-Minh L, Galasso R, et al. Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. Diabetologia. 2010;53(10):2167–76.PubMedCentralCrossRefPubMed

20.

Parnaud G, Bosco D, Berney T, et al. Proliferation of sorted human and rat beta cells. Diabetologia. 2008;51(1):91–100.CrossRefPubMed

21.

Banerjee M, Virtanen I, Palgi J, Korsgren O, Otonkoski T. Proliferation and plasticity of human beta cells on physiologically occurring laminin isoforms. Mol Cell Endocrinol. 2012;355(1):78–86.CrossRefPubMed

22.

Levitt HE, Cyphert TJ, Pascoe JL, et al. Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice. Diabetologia. 2011;54(3):572–82.PubMedCentralCrossRefPubMed

23.

Purwana I, Zheng J, Li X, et al. GABA promotes human beta-cell proliferation and modulates glucose homeostasis. Diabetes. 2014;63(12):4197–205.CrossRefPubMed

24.

Dirice E, Kahraman S, Jiang W, et al. Soluble factors secreted by T cells promote beta-cell proliferation. Diabetes. 2014;63(1):188–202.PubMedCentralCrossRefPubMed

25.

In't Veld P, De Munck N, Van Belle K, et al. Beta-cell replication is increased in donor organs from young patients after prolonged life support. Diabetes. 2010;59(7):1702–8.CrossRefPubMed

26.

Grapensparr L, Vasylovska S, Li Z, et al. Co-transplantation of human pancreatic islets with post-migratory neural crest stem cells increases beta-cell proliferation and vascular and neural regrowth. J Clin Endocrinol Metab. 2015;100(4):E583–90.CrossRefPubMed

27.

Takane KK, Kleinberger JW, Salim FG, Fiaschi-Taesch NM, Stewart AF. Regulated and reversible induction of adult human beta-cell replication. Diabetes. 2012;61(2):418–24.PubMedCentralCrossRefPubMed

28.

Fiaschi-Taesch N, Bigatel TA, Sicari B, et al. Survey of the human pancreatic beta-cell G1/S proteome reveals a potential therapeutic role for cdk-6 and cyclin D1 in enhancing human beta-cell replication and function in vivo. Diabetes. 2009;58(4):882–93.PubMedCentralCrossRefPubMed

29.

Fiaschi-Taesch NM, Salim F, Kleinberger J, et al. Induction of human beta-cell proliferation and engraftment using a single G1/S regulatory molecule, cdk6. Diabetes. 2010;59(8):1926–36.PubMedCentralCrossRefPubMed

30.

Imai J, Katagiri H, Yamada T, et al. Regulation of pancreatic beta cell mass by neuronal signals from the liver. Science. 2008;322(5905):1250–4.CrossRefPubMed

31.

Olerud J, Mokhtari D, Johansson M, et al. Thrombospondin-1: an islet endothelial cell signal of importance for {beta}-cell function. Diabetes. 2011;60(7):1946–54.PubMedCentralCrossRefPubMed

32.••

Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell. 2013;153(4):747–58. The publication in which betatrophin and its effects on beta cell proliferation in mice was first described.PubMedCentralCrossRefPubMed

33.

Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA. Butler PC: beta-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care. 2013;36(1):111–7.PubMedCentralCrossRefPubMed

34.

Sullivan BA, Hollister-Lock J, Bonner-Weir S, Weir GC. Reduced Ki67 staining in the postmortem state calls into question past conclusions about the lack of turnover of adult human beta-cells. Diabetes. 2015;64(5):1698–702.CrossRefPubMed

35.

Tyrberg B, Ustinov J, Otonkoski T, Andersson A. Stimulated endocrine cell proliferation and differentiation in transplanted human pancreatic islets: effects of the ob gene and compensatory growth of the implantation organ. Diabetes. 2001;50(2):301–7.CrossRefPubMed

36.

Gargani S, Thevenet J, Yuan JE, et al. Adaptive changes of human islets to an obesogenic environment in the mouse. Diabetologia. 2013;56(2):350–8.PubMedCentralCrossRefPubMed

37.

Dong XY, Pang XW, Yu ST, et al. Identification of genes differentially expressed in human hepatocellular carcinoma by a modified suppression subtractive hybridization method. Int J Cancer. 2004;112(2):239–48.CrossRefPubMed

38.

Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun. 2012;424(4):786–92.CrossRefPubMed

39.

Ren G, Kim JY, Smas CM. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab. 2012;303(3):E334–51.PubMedCentralCrossRefPubMed

40.

Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A. 2012;109(48):19751–6.PubMedCentralCrossRefPubMed

41.

Fu Z, Yao F, Abou-Samra AB, Zhang R. Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family. Biochem Biophys Res Commun. 2013;430(3):1126–31.CrossRefPubMed

42.

Jiao Y, Le Lay J, Yu M, Naji A, Kaestner KH. Elevated mouse hepatic betatrophin expression does not increase human beta-cell replication in the transplant setting. Diabetes. 2014;63(4):1283–8.PubMedCentralCrossRefPubMed

43.•

Wang Y, Quagliarini F, Gusarova V, et al. Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci U S A. 2013;110(40):16109–14. The authors have investigated mice lacking betatrophin and found no negative effect on glucose homeostasis.PubMedCentralCrossRefPubMed

44.••

Gusarova V, Alexa CA, Na E, et al. ANGPTL8/betatrophin does not control pancreatic beta cell expansion. Cell. 2014;159(3):691–6. Gusarova et al. found that mice lacking betatrophin have a normal development of beta cell mass and a normal response and increase in beta cell proliferation in response to insulin resistance which puts the relevance of betatrophin into question.PubMedCentralCrossRefPubMed

45.••

Cox AR, Lam CJ, Bonnyman CW, Chavez J, Rios JS, Kushner JA. Angiopoietin-like protein 8 (ANGPTL8)/betatrophin overexpression does not increase beta cell proliferation in mice. Diabetologia. 2015;58(7):1523–31. The authors have overexpressed betatrophin but do not find any increase in beta cell proliferation or beta cell mass which questions the findings of Ye et al. [32].PubMedCentralCrossRefPubMed

46.••

Abu-Farha M, Abubaker J, Al-Khairi I, et al. Higher plasma betatrophin/ANGPTL8 level in Type 2 Diabetes subjects does not correlate with blood glucose or insulin resistance. Sci Rep. 2015;5:10949. The largest study so far on circulating betatrophin levels in healthy- and individuals with type 2 diabetes. The betatrophin levels were found to be increased in type 2 diabetes.CrossRefPubMed

47.••

Espes D, Lau J, Carlsson PO. Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes. Diabetologia. 2014;57(1):50–3. The first publication on circulating betatrophin levels in plasma in healthy individuals and individuals with type 1 diabetes. In contrast to the animal model we found the levels of betatrophin to be increased in patients with type 1 diabetes.PubMedCentralCrossRefPubMed

48.•

Fenzl A, Itariu BK, Kosi L, et al. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia. 2014;57(6):1204–8. The first publication on circulating betatrophin levels in patients with type 2 diabetes, no difference in betatrophin levels between healthy- and individuals with type 2 diabetes was observed.CrossRefPubMed

49.

Espes D, Martinell M, Carlsson PO. Increased circulating betatrophin concentrations in patients with type 2 diabetes. Int J Endocrinol. 2014;2014:323407.PubMedCentralCrossRefPubMed

50.

Chen X, Lu P, He W, et al. Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance. J Clin Endocrinol Metab. 2015;100(1):E96–100.CrossRefPubMed

51.

Wu S, Gao H, Ma Y, Fu L, Zhang C, Luo X. Characterisation of betatrophin concentrations in childhood and adolescent obesity and insulin resistance. Pediatr Diabetes. 2014.

52.

Gomez-Ambrosi J, Pascual E, Catalan V, et al. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab. 2014;99(10):E2004–9.CrossRefPubMed

53.

Fu Z, Berhane F, Fite A, Seyoum B, Abou-Samra AB, Zhang R. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci Rep. 2014;4:5013.PubMed

54.

Hu H, Sun W, Yu S, et al. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care. 2014;37(10):2718–22.CrossRefPubMed

55.

Guo K, Lu J, Yu H, et al. Serum betatrophin concentrations are significantly increased in overweight but not in obese or type 2 diabetic individuals. Obesity (Silver Spring). 2015;23(4):793–7.CrossRef

56.

Tokumoto S, Hamamoto Y, Fujimoto K, et al. Correlation of circulating betatrophin concentrations with insulin secretion capacity, evaluated by glucagon stimulation tests. Diabet Med. 2015;32(5):653–6.CrossRefPubMed

57.

Xie X, Gao T, Yang M, et al. Associations of betatrophin levels with irisin in Chinese women with normal glucose tolerance. Diabetol Metab Syndr. 2015;7:26.PubMedCentralCrossRefPubMed

58.

Gokulakrishnan K, Manokaran K, Pandey GK, et al. Relationship of betatrophin with youth onset type 2 diabetes among Asian Indians. Diabetes Res Clin Pract. 2015;109(1):71–6.CrossRefPubMed

59.•

Fu Z, Abou-Samra AB, Zhang R. An explanation for recent discrepancies in levels of human circulating betatrophin. Diabetologia. 2014;57(10):2232–4. This study describe the different ELISA kits used to measure betatrophin which explain some of the differences in the published levels and correlations of betatrophin.CrossRefPubMed

60.

Yamada H, Saito T, Aoki A, et al. Circulating betatrophin is elevated in patients with type 1 and type 2 diabetes. Endocr J. 2015;62(5):417–21.CrossRefPubMed

Titel: Betatrophin in Diabetes Mellitus: the Epidemiological Evidence in Humans
verfasst von: Daniel Espes
Mats Martinell
Hanna Liljebäck
Per-Ola Carlsson
Publikationsdatum: 01.12.2015
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 12/2015
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-015-0676-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2015

Is Insulin Resistance a Feature of or a Primary Risk Factor for Cardiovascular Disease?

Affordable Care Act and Diabetes Mellitus

Shared Decision-Making in Diabetes Care

Epidemiology of NAFLD and Type 2 Diabetes: Health Disparities Among Persons of Hispanic Origin

Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?